Entities

Valentin Tonnel is an investment manager in the Q4 2024 WE Life Sciences roster, joined November 2023 after corporate-finance advisory work supporting strategy and financing. Holds a molecular-biology/genetics master’s degree from Louvain and MIT healthcare-finance professional certificate. The dated public roster does not by itself establish a new employment start day or uninterrupted tenure through October 2026.

Dr. Yves Ribeill, PhD, currently works as a Partner and Entrepreneur in Residence at Argobio Studio in Paris, France. He is a seasoned entrepreneur who founded Scynexis, Inc (NASDAQ: SCYX) and served as its President from 1999 to 2015, as well as its Chief Executive Officer from 1999 to 2015. Prior to his tenure at Scynexis, Inc., he held various positions at Rhone-Poulenc, Aventis, where he spent 20 years of his international career and served as Director of Chemistry for the Anti-Infective Group. Throughout his career, he has played a key role in the development and FDA approval of numerous drugs at Rhone-Poulenc and Scynexis. He has also served on the board of directors for various biotech companies in Europe and the US, and currently chairs the board of Calyxt (NASDAQ:CLXT). Dr. Ribeill holds a Ph.D. in Chemistry from the University of Montpellier (France) and has authored over 26 publications and 17 patents. He is a member of the Scientific Advisory Board of DNDi, and has previously served on the Scientific Advisory Committee of the World Health Organization and the Medicine Malaria Venture in Geneva.

Elkedonia is a Franco-Belgian biotechnology company launched in 2025, headquartered in Strasbourg with an affiliate in Charleroi. Built by Argobio from research led by Jocelyne Caboche at Sorbonne University, it develops small-molecule inhibitors of the intracellular ELK1 protein for treatment-resistant depression and other neuropsychiatric disorders. Its preclinical neuroplastogen program aims to restore neuroplasticity through a non-synaptic mechanism. Biomarker research and AI support its precision-medicine strategy for patient selection and development.

Ysios Capital is a Spanish venture capital firm founded in 2008, with offices in Barcelona and San Sebastián. It invests globally in early- and mid-stage biotechnology companies developing novel therapeutic drugs and platforms for diseases with high unmet medical need. Its neuroscience portfolio includes Synendos, Engrail, Kynexis, Minoryx and Neurona. Alongside its established venture funds, its InceptionBio strategy focuses on company creation, technology transfer and early scientific projects, particularly in Spain.

Thomas Harth is named on Anaconda Biomed’s current public board of directors. The issuer identifies the affiliation as YSIOS CAPITAL. This confirms the board relationship without establishing a personal investment.

Thierry Laugel appears in Idinvest Partners’ August2020 primary directory as Strategic Advisor. The publisher separately classified this as an external strategic or investment advisory affiliation, rather than full-time operating staff. The named historical role is distinguished from the preserved later Eurazeo affiliations. Idinvest became Eurazeo Investment Manager and was subsequently absorbed into Eurazeo Global Investor. Joining and departure days and unpublished prior career or education details are not inferred.

Kurma Partners is a European healthcare and biotechnology investment firm founded in 2009, based in Paris with investing activity in Germany. It finances companies from scientific company creation and early development through expansion, across Biofund, Diagnostic and Growth Opportunities strategies. Working with European academic research groups, it helps translate discoveries into medicines, medical devices and diagnostics. Its neuroscience investments include Synendos Therapeutics, developing endocannabinoid-system drugs for CNS disorders.

Rémi Droller appears in Idinvest Partners’ August2020 primary directory as Strategic Advisor. The publisher separately classified this as an external strategic or investment advisory affiliation, rather than full-time operating staff. The named historical role is distinguished from the preserved later Eurazeo affiliations. Idinvest became Eurazeo Investment Manager and was subsequently absorbed into Eurazeo Global Investor. Joining and departure days and unpublished prior career or education details are not inferred.

Synendos Therapeutics AG is a Basel-based clinical-stage neuroscience company founded in 2019 from research at the University of Bern and NCCR TransCure. It develops selective endocannabinoid reuptake inhibitors to modulate endocannabinoid signalling for neuropsychiatric disorders. Lead candidate SYT-510 completed Phase 1 studies in 2025 and entered a Phase 2 trial in generalized anxiety disorder in May 2026. Its development strategy also addresses anxiety, mood and stress-related conditions including PTSD.

George Garibaldi is a neuroscience drug-development physician and current Synendos Therapeutics Chief Medical Officer. Noema’s2020 issuer release identifies him as its Chief Medical Officer, and Newron’s2026 primary biography confirms that he co-founded Noema. The Noema position is historical and does not replace his existing Synendos role.

Casey Tansey is a USVP general partner who joined inApril2005 after operating medical-device companies. His investment interests include minimally invasive devices, cardiovascular care, orthopedics and neurology. He led Epicor Medical through its acquisition by St.Jude Medical and previously led Heartport and worked at Baxter’s cardiovascular division. Published portfolio board relationships include Luminopia, MicroTransponder, Neuros Medical, ShiraTronics and HeartFlow. He holds BS and MBA degrees from the College of Notre Dame in Belmont. Casey Tansey is listed by Mobia Medical (formerly MicroTransponder) as Board Member. He is a managing partner at U.S. Venture Partners; the Mobia SEC prospectus separately discloses a personal USD2 million 2026 convertible-note investment, distinct from USVP institutional funds. Casey Tansey is a current Iantrek board member; the company identifies his U.S. Venture Partners general-partner affiliation. Institutional fund participation is distinct from personal investing.

Debra Snowdale is Novocuff’s CFO and is also published as ShiraTronics’ CFO. Her own ShiraTronics biography describes more than twenty years in medical-device finance leadership and advisory work, with experience at ExclusiveCFO, Ernst & Young and Philips Medical Systems.

Joyce Erony is an Amzak Health managing partner and medical-device investor, previously a Signet Healthcare Partners managing director.

Provides dynamic single-cell analysis for drug discovery and cell-therapy development. Its TIMING platform combines time-lapse imaging and visual AI to measure cell movement, activation, interactions and killing over time, helping researchers evaluate immune-cell function and therapeutic candidates.

Clinical-stage biotechnology company developing treatments for serious underserved diseases. Formerly Cortexyme, it is advancing LAM-001, an inhaled rapamycin candidate for pulmonary diseases, following its May 2026 acquisition of Orphai Therapeutics. Its earlier eDSP program used red-blood-cell drug encapsulation for ataxia-telangiectasia; the January 2026 Phase 3 study did not meet its primary endpoint.

Life-sciences investor and biotechnology board director, published as a managing partner at Sands Capital.

Sunstone Life Science Ventures is an independent European venture capital firm founded in 2007, investing in early-stage companies developing novel human therapeutics. Based in Copenhagen, it supports scientific, clinical and business development through its investment team and external Business Development Advisory Board. Its neuroscience investments include Neumirna Therapeutics, developing RNA therapies for neurological disorders, and Synendos Therapeutics, developing endocannabinoid-system medicines for central nervous system disorders. Its funds also include historical medical technology and diagnostics investments.

Evidation Health co-founder identified in Akili’s2022 public-board directory; resigned from Akili’s board July2,2024 at the acquisition. Dated board affiliation is preserved separately from outside advisory roles.

Søren Rask Tange is published as Finance Director by both Heartcore Capital and Sunstone Life Science Ventures. Their own directories link the same individual LinkedIn identity.

Business angel named as an investor in Maculaser's 2021 financing.

Andreas Wallnöfer advises ClavystBio and has held senior Roche research and development positions, including cardiovascular and metabolism leadership. His investing career includes BioMedPartners and Jeito Capital. He holds a pharmacology doctorate from Basel and an executive MBA from IMD.

Neumirna Therapeutics is a Copenhagen-based biotechnology company developing RNA medicines for neurological disorders. Its platform targets microRNAs with antisense oligonucleotides to address disease mechanisms. Its lead program, NMT.001, focuses on drug-resistant epilepsy, with a further program in Parkinson's disease. Founded by neuroscience and RNA biology specialists, the company operates across Copenhagen, Basel and Boston.

Timothy Lu is a scientific co-founder, board member and scientific advisory co-chair of Engine Biosciences, as published in its April2026 directory. His synthetic-biology research at MIT helped establish the technology; he also co-founded Senti Biosciences and several other biotechnology companies. Goodman Capital’s archived May2019 primary team directory additionally identifies Timothy Lu as Advisor (historical published affiliation). This Singapore firm invested its principals’ and families’ capital; the role is source-qualified historical and does not imply a currently held appointment or personal cash investment.

Invivo Partners is a Barcelona-based venture capital firm investing in early-stage biotechnology and in companies at the intersection of AI and deep tech. Its life science strategy emphasizes advanced therapies, synthetic biology and disease-modifying medicines, including neurological disorders. It invests from company creation and seed through Series A, with a European focus and particular interest in Spain, and supports portfolio development with investment and scientific expertise.

Partner at Invivo Partners and chairwoman of Eclova Therapeutics. She holds a PhD in Biotechnology and worked in oncology gene therapy and technology transfer at Vall d’Hebron Research Institute before entering venture capital.

Innovestor is a Finnish investment group based in Helsinki, with strategies in venture capital, life sciences, corporate venturing, energy storage and real estate. It backs early-stage technology and healthcare companies across the Nordics, including AI, sustainable technologies, medical devices and RNA therapeutics for neurological diseases. Its venture teams combine investing experience with scientific and operational expertise and support company building and follow-on financing.

Develops extracellular-vesicle delivery technology for gene therapies. Its platform engineers cell-derived vesicles to carry genetic payloads to target tissues, aiming to provide alternatives to viral vectors and improve how genetic medicines reach cells in the body.

Pfizer Ventures partner and business-development executive with a background in pharmaceutical chemistry and research. TRexBio director since January 2026, with resignation planned before IPO registration effectiveness. PfizerVentures primarypublished affiliation: Vice President, WWBD / Partner. Christopher O’Donnell, PhD is a Partner at Pfizer Ventures and Vice President, Worldwide Business Development. Chris is responsible for identifying, evaluating, making, and managing equity investments aligned with the future directions of Pfizer. He currently has responsibility for Pfizer’s investments in Arrakis Therapeutics, Cartography Biosciences, Circle Pharma, Enlaza Therapeutics, Incendia Therapeutics, Kestrel Therapeutics, MindImmune, Nimbus, Pyxis Oncology (PYXS), Storm Therapeutics, Strata Oncology, TRex Bio, and Triana Biomedicines. He is also responsible for managing our investment in the Avant Bio, Mission BioCapital and Phoenix Venture Partners funds. His prior investment responsibilities include Adapsyn Bioscience, Arkuda Therapeutics, BioAtla (BCAB), Kymera Therapeutics (KYMR), Mitokinin, Morphic Therapeutic (MORF), and Petra Pharma. Chris brings 25+ years of scientific and corporate leadership, a strong track record of delivering clinical candidates across multiple disease areas and modalities, and proven ability to build and lead highly engaged teams and companies. At Pfizer, he built and led the Applied Synthesis Technologies group within Pfizer R&D to help accelerate the delivery of Pfizer’s small molecule portfolio. Prior to that, Chris built and led Pfizer’s Antibody Drug Conjugate Oncology Medicinal Chemistry group which delivered new linker, payload and conjugation methods resulting in over 10 conjugates entering clinical development. Chris started his career in the Neuroscience Medicinal Chemistry group where he invented and helped deliver numerous clinical candidates. Chris received his BS in Chemistry from the University of Illinois-Urbana/Champaign and his PhD in Chemistry from the University of Wisconsin-Madison and joined Pfizer after completing post-doctoral studies at the University of California – Irvine.

Delos Capital partner since 2024, after serving as senior adviser and operating partner. Previously held scientific leadership roles at Moderna, including New Venture Labs and Moderna Genomics. Also serves on the boards of STRM.BIO and TRexBio, with the latter resignation planned before IPO registration effectiveness; based in Cambridge.

Northpond Ventures managing director and Scipher Medicine board director, with a background in life sciences investing. Northpond’s current team lists Steve Liapis as Managing Director.

Delos Capital partner and founding team member, with experience in life sciences investment banking and venture investing. Serves on portfolio-company boards including STRM.BIO, Eccogene and Zenas; previously worked at Goldman Sachs. Based in Hong Kong.

Develops cell therapies by programming a patient’s B cells to produce therapeutic proteins. Its Immune System Programming platform aims to turn these antibody-producing cells into a lasting source of medicines for rare genetic diseases and other conditions with unmet treatment needs.

Develops monoclonal antibody therapies designed to disrupt barriers in the tumor microenvironment. Its research targets structural and biochemical mechanisms that keep immune cells out of tumors, with the aim of improving the activity of cancer immunotherapies.

Develops fermentation and biomanufacturing technology that converts renewable feedstocks into chemicals and performance materials. Its engineered microbes and production processes are designed to reduce carbon loss and replace petroleum-derived ingredients in products such as absorbent polymers, personal-care materials and industrial chemicals.

Chris Gibson is the Recursion co-founder and former CEO, joining Dimension in its ownJuly29,2026 announcement. The firm also publicly reposted his direct interview identifying the operating-partner role; he is separately qualified because the current homepage13-person directory does not list operating partners. His existing A-Alpha Bio strategic/scientific adviser and Synteny adviser roles are preserved. A-Alpha’s own individually named portrait verifies the shared identity. An employer role does not infer a personal investment check or end any unrelated adviser appointment.

Aizen board member and Madrona investor, independently identified in the issuer’s November2024 financing announcement.

Managing Partner at KdT Ventures; scientist with experience helping spin out biotechnology companies, joined the firm in2018.

Develops enzymatic technology for manufacturing RNA medicines. Its ezRNA platform uses engineered enzymes to synthesize RNA, including chemically modified sequences, to support drug discovery and scalable production of therapeutic oligonucleotides.

Develops biologic medicines targeting tumor-macrophage hybrid cells implicated in cancer metastasis, treatment resistance and recurrence. Its discovery platform builds on licensed Columbia University research to investigate new ways of eliminating these cancer-associated cells.

Develops a cell-based platform for fertility treatment intended to support hormone-free in vitro fertilization. Its preclinical research applies reproductive biology and cell engineering to egg maturation, with the aim of reducing the injections and hormonal stimulation used in conventional IVF. The platform is investigational and is not yet cleared for clinical use.

Jefferson Life Sciences strategic adviser and principal of JBW Consulting. Previously served as executive vice president, chief operating officer and chief business officer at Dicerna Pharmaceuticals; also serves on EnPlusOne Bio's board.

Paxton Major serves as Managing Director at Northpond Ventures, a science-driven investor in biotechnology, research tools, diagnostics and digital health.

Sara Vaughn, MD, is Chief Medical Officer of Clair Health; her published professional speaker biography describes the role as fractional. She is a physician specializing in obstetrics and gynecology and reproductive endocrinology. Vitra Labs also names her as a clinical advisory board member; that existing separate advisory role is preserved.

Previa Medical is a Lyon-based AI company developing digital biomarkers that help hospital teams anticipate acute deterioration and life-threatening emergencies. Its platform analyzes electronic medical records and clinical data in real time and alerts healthcare professionals to risks including sepsis, acute kidney injury, respiratory distress and cardiac arrest. Its SEPSI-SCORE product focuses on early sepsis detection and is supported by clinical research.

Maculaser is an Espoo-based Finnish medical technology company developing a temperature-controlled retinal laser treatment, rooted in research at Aalto University. Its patented system aims to deliver personalized, non-damaging retinal heating that activates cellular protective responses. The company is working toward clinical validation and commercial readiness for retinal disorders, including age-related macular degeneration and macular edema.

TheraSonic is a Paris-based medical-device company developing non-invasive focused ultrasound to temporarily open the blood-brain barrier and improve targeted delivery of medicines to the brain. Spun out of CEA and CNRS research, its platform combines robotic positioning, neuronavigation and real-time ultrasound dosimetry. It is progressing through clinical development, initially addressing brain cancers and metastases, with Gustave Roussy as clinical-trial sponsor.

ZEISS Ventures is the corporate venture capital and venture-building arm of the ZEISS Group. It invests in external startups and develops internal ventures and technologies beyond the group's core businesses. Its focus includes industrial technology, AI and machine vision, robotics, photonics, semiconductors, medical devices and life sciences, generally targeting pre-Series A and Series A companies in Europe and North America.

Gustave Roussy Transfert is the technology-transfer and research-commercialization subsidiary of France's Gustave Roussy cancer institute. It protects intellectual property, structures academic and industrial partnerships, and helps create and develop startups in biotechnology, medical devices and AI. It also takes equity stakes, including in TheraSonic's focused-ultrasound brain drug-delivery technology, and provides access to scientific, clinical and business expertise.

Builds multimodal AI foundation models of human state, connecting brain signals, physiology, behavior and environmental data. Its research and data-collection platform aims to support neuroscience, neurotechnology and systems that interact with people by learning representations of brains, bodies and their surroundings.

Develops precision therapies for autoimmune diseases by targeting the cells responsible for dysfunctional immune responses. It applies genomics and AI to disease biology and therapeutic design, aiming to reset immune function rather than only manage symptoms.

Polaris managing partner investing in healthcare and early biotechnology. Her current biography confirms Alnylam board chair and Elevance Health director affiliations and her work with QurAlis and other Polaris companies.